BamSEC and AlphaSense Join Forces
Learn More

Emmaus Life Sciences Incorporation

OTC: EMMA    
Share price (12/20/24): $0.01    
Market cap (12/20/24): $741 thousand
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 21 pages Purchase Price: $880,000.00 Purchased Amount: 1,298,000.00 Average Projected Monthly Sales: $2,231,558.83 Specified Percentage: 15 % (Average Projected Monthly Sales X Specified Percentage / Average Business Days in a Calendar Month) Initial Weekly Amount: Please See Exhibit B-4 Origination Fee: $80,000.00 (To Be Deducted From the Purchase Price) Payment Will Be Withdrawn Every Monday Account for the Deposit of All Future Receipts: Bank: California Bank & Trust Account No
12/34/56
EX-10.1
from 10-Q 22 pages Agreement for the Purchase and Sale of Future Receipts
12/34/56
EX-10.4
from 10-Q 10 pages Emmaus Life Sciences, Inc. Promissory Note
12/34/56
EX-10.41
from 10-K 5 pages Emmaus Life Sciences, Inc. Promissory Note
12/34/56
EX-10.23
from 10-K 3 pages Emmaus Life Sciences, Inc. Amendment No. 4 to Convertible Promissory Note Emi Holding, Inc
12/34/56
EX-10.20
from 10-K 3 pages Emmaus Life Sciences, Inc. Amendment No. 1 to Convertible Promissory Note
12/34/56
EX-10.2
from 8-K 1 page This Joinder Areement and Amendment to Transfer Restriction and Voting Agreement (This “Agreement”) Is Made With Reference to the Transfer Restriction and Voting Agreement (The “Voting Agreement”) Made and Entered Into as of February 8, 2021 by and Among Between Emmaus Life Sciences, Inc., a Delaware Corporation (The “Company”), and Each Purchaser Identified on the Purchaser Signature Pages Thereto (Each, Including Its Successors and Permitted Assigns, the “Purchaser”), With Reference to the Following Facts: Wheras, the Undersigned Investor Is a Successor and Assign of One or More of the “Convertible Notes” Referred to in the Voting Agreement; And
12/34/56
EX-10.1
from 8-K 6 pages Exchange Agreement
12/34/56
EX-10.1
from 8-K 4 pages Exchange Agreement
12/34/56
EX-10.3
from 10-Q 105 pages ** Please Read Carefully **
12/34/56
EX-10.2
from 10-Q 54 pages Offer Summary – Revenue Based Financing
12/34/56
EX-10.1
from 10-Q 3 pages Offer Summary – Revenue Purchase Agreement
12/34/56
EX-10.4
from 10-Q 29 pages This Is an Agreement Dated 06/14/2023 by and Between Slate Advance (“Sa2”) and Each Merchant Listed Below (“Merchant”). Merchant’s Legal Name: Emmaus Medical, Inc. and All Entities Listed on Addendum - "Merchant List" D/B/A: Emmaus Medical Fed Id #: 87-0419387 Type of Entity: Corporation Business Address 21250 Hawthorne Boulevard City: Torrance State: Ca Zip:90503 Contact Address City: State: Zip: Email Address: Phone Telephone
12/34/56
EX-10.3
from 10-Q 5 pages Emmaus Medical Japan Promissory Note
12/34/56
EX-10.2
from 10-Q 53 pages Apex Funding Source LLC
12/34/56
EX-10.1
from 10-Q 5 pages Emmaus Life Sciences, Inc. Promissory Note
12/34/56
EX-10.6
from 10-Q 4 pages Emmaus Life Sciences, Inc. Promissory Note
12/34/56
EX-10.5
from 10-Q 4 pages Emmaus Life Sciences, Inc. Promissory Note
12/34/56
EX-10.4
from 10-Q 56 pages Offer Summary – Revenue Based Financing
12/34/56
EX-10.3
from 10-Q 23 pages Revenue Purchase Agreement Purchase and Sale of Future Receipts
12/34/56